Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Nicholas A TurnerSmitha ZaharoffHeather KingScott EvansToshimitsu HamasakiThomas LodiseVarduhi GhazaryanTatiana BeresnevTodd RiccobeneRinal PatelSarah B DoernbergUrania RappoVance G FowlerThomas L Hollandnull nullPublished in: Trials (2022)
US National Institutes of Health ClinicalTrials.gov NCT04775953 . Registered on 1 March 2021.